NEW YORK, Nov. 7 – Myriad Genetics said Wednesday its fiscal first quarter revenues increased 22 percent to $13.2 million, compared with $10.8 million a year ago, boosted by strong sales of the company’s diagnostic products.

Myriad of Salt Lake City said that product revenues alone increased 81 percent in the quarter to $5.5 million. The company manufactures the BracAnalysis product for breast and ovarian cancer and the Colaris product for colon and uterine cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.